Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Elan and Wyeth's Alzheimer's hope fails to impress

This article was originally published in Scrip

Executive Summary

Elanand Wyethhave presented further disappointing results from a closely watched and failed Phase II trial of bapineuzumab, an investigational Alzheimer's disease treatment. Observers had had high hopes for the drug as it is the most developmentally advanced monoclonal antibody directly targeting beta-amyloid, a class of drugs thought to have the potential to reverse patients' neurodegeneration.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts